Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103100 | 0.98 | OPRK1 (0.54) | OPRK1ALDH1A1HTTMAPK1LMNA | |
| SCHEMBL27159916 | 0.84 | OPRK1 (0.48) | OPRK1ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL21170840 | 0.84 | OPRK1 (0.69) | OPRK1ALDH1A1HTTMAPK1LMNA | |
| SCHEMBL16944616 | 0.82 | OPRK1 (0.78) | OPRK1 | |
| SCHEMBL13010703 | 0.79 | HTT (0.50) | OPRK1HTTMAPK1LMNAMAPT | |
| SCHEMBL6103809 | 0.78 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL6104537 | 0.77 | OPRK1 (0.58) | OPRK1 | |
| SCHEMBL2213986 | 0.76 | OPRK1 (0.49) | OPRK1ALDH1A1HTTMAPT | |
| SCHEMBL18994652 | 0.76 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL14470632 | 0.75 | SCN10A (0.48) | ALDH1A1LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2884978-B1 | NOVEL KAPPA OPIOID LIGANDS | SCRIPPS RESEARCH INST (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
| EP-2178876-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | AstraZeneca AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010801-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | OPRK1 664/4885ALDH1A1 246/4885HTT 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.